Sepiapterin (2) – Sephience®
Hyperphenylalaninaemia associated with phenylketonuria
Characteristics
| Start date | 15.11.2026 |
|---|---|
| Resolution | 05.05.2027 – active procedure |
| INN | Sepiapterin |
| Brand name | Sephience® |
| Pharm. company | PTC Therapeutics International Limited |
| G-BA Procedure ID | D-1395 |
| Therapeutic area | Metabolic diseases |
| Reason for procedure | Reassessment: Loss of orphan status |
Associated procedures
| Sepiapterin (2) | Sephience® | PTC Therapeutics International Limited | Hyperphenylalaninaemia associated with phenylketonuria | n.d. | active procedure | |
| Sepiapterin (1) | Sephience® | PTC Therapeutics International Limited | Hyperphenylalaninaemia in phenylketonuria | 4,700–6,800 | 100% Hint for non-quantifiable additional benefit Orphan |
<< List of all resolutions